1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

WHO Issues Warning on Falsified Medicines for Diabetes and Weight Loss

24 Jun 2024
Admin
News Article

WHO Issues Warning on Falsified Medicines for Diabetes and Weight Loss

World Health Organization issues warning on falsified medicines used for diabetes treatment and weight loss

Overview

The World Health Organization (WHO) issued a medical product alert on falsified semaglutides, the type of medicines that are used for treatment of type 2 diabetes and obesity in some countries.

Falsified Product of Semaglutide

The alert addresses 3 falsified batches of product of semaglutide class of medicines (of specific brand Ozempic), which have been detected in Brazil in October 2023, the United Kingdom of Great Britain and Northern Ireland in October 2023, and the United States of America in December 2023.
WHO Global Surveillance and Monitoring System (GSMS) has been observing increased reports on falsified semaglutide products in all geographical regions since 2022.
This is the first official notice issued by WHO after confirmation of some of the reports.

From WHO

“WHO advises healthcare professionals, regulatory authorities and the public be aware of these falsified batches of medicines,” said Dr Yukiko Nakatani, WHO Assistant Director-General for Essential Medicines and Health Products.
“We call on stakeholders to stop any usage of suspicious medicines and report to relevant authorities”.

About Semaglutides

The semaglutides, including the specific brand product that has been falsified, are prescribed to people with type 2 diabetes in order to lower their blood sugar levels.
Semaglutides also reduce the risk of cardiovascular events.
Most semaglutide products must be injected under the skin on a weekly basis but they are also available as tablets taken by mouth daily.
These medicines are shown to suppress appetite in addition to lowering blood sugar levels, and therefore are being increasingly prescribed for weight loss in some countries.

Reports on Falsification

WHO has been observing increased demand for these medicines as well as reports on falsification.
These falsified products could have harmful effects to people’s health; if the products don’t have the necessary raw components, falsified medicines can lead to health complications resulting from unmanaged blood glucose levels or weight.
In other cases, another undeclared active ingredient may be contained in the injection device, e.g. insulin, leading to an unpredictable range of health risks or complications.

Semaglutides & other Treatment Options

Semaglutides are not part of WHO-recommended treatments for diabetes management due to their current high cost.
The cost barrier makes these products unsuitable for a public health approach, which aims to ensure the widest possible access to medicines at the population level and to strike a balance between the best-established standard of care and what is feasible on a large scale in resource-limited settings. Also, there are more affordable treatments available for diabetes, with similar effects to those of semaglutides on blood sugar and cardiovascular risk.

Rapid Advice Guideline for GLP-1 RAs

WHO is currently working on a rapid advice guideline on possible use of GLP-1 RAs, including semaglutides, for treatment of obesity in adults and as part of a more comprehensive model of care.
The term GLP-1 RAs stands for glucagon-like peptide-1 receptor agonists, which include semaglutides, for a class of medicines used for diabetes treatment to lower blood sugar and support weight loss.

Protection from Falsified Medicines

To protect themselves from falsified medicines and their harmful effects, patients who are using these products can take actions such as buying medicines with prescriptions from licensed physicians and avoid buying medicines from unfamiliar or unverified sources, such as those that may be found online.

Precutions

People should always check packaging and expiry dates of medicines when they buy them, and use the products as prescribed.
In the case of injectable semaglutides, patients should ensure they are stored in the refrigerator.
All notifications on falsified medicines can be sent to WHO via rapidalert@who.int.